ישראל -
עברית -
Ministry of Health
בסרמי 250 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
ישראל -
עברית -
Ministry of Health
קלריטון
fischer pharmaceuticals ltd - benzalkonium chloride - טיפות עיניים - benzalkonium chloride 0.01 % - benzalkonium - benzalkonium - for rinsing and soothing the eyes against irritation due to various causes such as: dust, smoke, plants etc. for first aid use in helping remove a foreign body from the eye.
ישראל -
עברית -
Ministry of Health
טמיפלו 75 מג
roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.
ישראל -
עברית -
Ministry of Health
טמיפלו 75 מג
roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.